undamentalytics Newsletter
Sign in

Zevra Therapeutics, Inc. income statement

In fiscal 2025, Zevra Therapeutics, Inc. reported revenue of $106m, up 350.9% on the year before, operating income of −$62.9m (a -59.1% margin) and net income of $83.2m, or $1.35 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0000131329102724106136
Cost of revenue———010—203———
Gross profit———03—271025———
Research and development3121442199102040421315
Selling, general and administrative———————1534557875
General and administrative159131189—————
Operating income−5−16−23−56−20−68−43−50−87−6382
Interest expense023555002786
Income before tax−5−24−55−57−25−13−9−27−46−908769
Income tax−0−00−0−0−00−0015311
Net income−5−24−55−56−25−13−9−27−46−1068358
Diluted EPS−$11.73−$3.42−$118.72−$50.40−$13.23−$3.21−$2.11——−$2.28$1.35$0.97
Diluted shares (average)———1m2m4m30m34m35m46m57m60m
EBITDA−5−16−23−56−20−58−42−49−81−5984

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NAII vs ZVRANAGE vs ZVRAHRTX vs ZVRAETON vs ZVRA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Zevra Therapeutics, Inc.